HCPCS code J2505: Deleted in 2022, now bills as J2506

Key Takeaways

HCPCS code J2505 (Injection, pegfilgrastim, 6 mg) was deleted by CMS effective December 31, 2021. CMS eliminated grace periods for discontinued HCPCS codes back in 2010, so claims dated January 1, 2022 or later must use the replacement code, J2506, with no transition window.

J2506 bills per 0.5 mg, not per 6 mg. A standard 6 mg pegfilgrastim dose is 12 units, not 1 unit. Copying the old J2505 unit logic into J2506 is the most common denial trigger in this switch.

The Neulasta Onpro on-body injector is not billed with a separate drug HCPCS code. Bill the drug under J2506 (or the matching biosimilar Q-code) and identify the delivery method with the administration CPT code: 96377 for the on-body injector, 96372 for a manual or prefilled-syringe injection.

Practice management software like Pabau helps oncology and infusion practices keep drug administration billing, HCPCS code tables, and modifier rules current, so a deleted code like J2505 does not sit in a charge master for years after CMS retires it.

If you’re still billing HCPCS code J2505 for pegfilgrastim (Neulasta) in 2026, stop. The code doesn’t exist anymore. CMS deleted J2505 effective December 31, 2021, and replaced it with J2506, which bills at a different unit size entirely.

That change alone has caused a wave of denied claims. Practices that carry their old J2505 logic into J2506 without adjusting units end up billing 1 unit instead of 12 for a standard 6 mg dose.

This guide covers the current J2506 billing rules, the correct Onpro on-body injector administration coding, the biosimilar Q-code crosswalk, and the denial triggers specific to this code in 2026.

HCPCS code J2505 is deleted: here’s what to bill instead

HCPCS code J2505 was a Level II code maintained by the Centers for Medicare and Medicaid Services (CMS) with the long descriptor Injection, pegfilgrastim, 6 mg. CMS deleted it as part of the annual HCPCS update, effective for dates of service on or after January 1, 2022. The replacement code is J2506 (Injection, pegfilgrastim, excludes biosimilar, 0.5 mg).

This isn’t a soft transition. CMS eliminated the standard grace period for discontinued HCPCS codes back in 2010, so there was never a window where both codes were billable side by side. Any claim for a date of service on or after January 1, 2022 that still carries J2505 will deny.

If your practice management system, superbill, or charge master still has J2505 listed as an active code, that’s a live denial risk. Update it to J2506 today, not at your next annual code review.

Pegfilgrastim itself hasn’t changed. It’s a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies. The brand-name originator product is Neulasta, manufactured by Amgen. What changed is only the HCPCS code and its billing unit size, covered in detail below.

J2506 code details at a glance

The table below consolidates the key reference fields for HCPCS code J2506, the active 2026 code for pegfilgrastim. Use it as a quick lookup during claim preparation.

J2506 billing units: how to bill correctly

One billing unit of HCPCS code J2506 equals 0.5 mg of pegfilgrastim, not 6 mg and not 1 mg. This is the detail that trips up practices making the switch from J2505. Under the old code, 1 unit covered the entire standard 6 mg dose. Under J2506, that same 6 mg dose is 12 units.

Bill 1 unit for J2506 and the claim will look like you administered 0.5 mg instead of 6 mg. That’s an underbilling error that either denies outright or gets reimbursed at a fraction of the correct rate.

The table below shows the unit conversion for the doses billing teams most commonly encounter.

Practices managing complex drug administration workflows benefit from structured claims management software that enforces current unit rules at the point of claim entry, reducing the likelihood of a front-end edit before the claim leaves the practice.

Place of service codes for J2506

Place of service (POS) affects both the applicable modifier and the reimbursement rate. The two most common settings are:

• POS 11 (Physician office): Bill J2506 at 12 units for a standard 6 mg dose. Reimbursement is ASP + 6%.
• POS 22 (Hospital outpatient department): Bill J2506 under the OPPS. Reimbursement is ASP + 6%, though the on-body injector administration CPT code may be bundled into the facility payment (see the Onpro section below).
• POS 19/21/other facility: Confirm with the specific MAC’s coverage article, as incident-to rules and payment methodologies vary.

Applicable modifiers: JW and JZ

Modifier JW (drug amount discarded) has been required on Part B drug claims with wastage since 2017. Modifier JZ (attesting to zero wastage) became optional on January 1, 2023, and mandatory from July 1, 2023, with claims edits and rejections for missing JZ starting in October 2023.

In practice, every J2506 claim needs either JW (if any of the vial was discarded) or JZ (if none was). There’s no longer a middle ground where neither modifier is required. Confirm with your MAC’s specific billing instructions for any additional modifier requirements under HCPCS code J2506.

Medicare coverage for HCPCS code J2506

Medicare Part B covers J2506 when pegfilgrastim is administered to a patient receiving myelosuppressive anti-cancer drugs for a non-myeloid malignancy, as documented by the treating oncologist.

Coverage requires that the drug is administered by or under the supervision of a physician (incident-to rules), consistent with guidance from the CMS Physician Fee Schedule and MAC-specific local coverage articles.

Covered diagnoses and required ICD-10 codes

Every J2506 claim requires a supporting ICD-10-CM diagnosis code. The primary diagnosis should reflect the patient’s underlying malignancy receiving chemotherapy. Common covered primary diagnoses include codes from the C00-C96 range (malignant neoplasms).

Secondary codes may include chemotherapy encounter codes such as Z51.11 (encounter for antineoplastic chemotherapy). Verify the exact covered diagnosis list against your MAC’s coverage article on the CMS Medicare Coverage Database, as individual MAC policies may specify additional or more restrictive criteria.

Off-label uses of pegfilgrastim, including stem-cell mobilization sometimes explored by regenerative medicine practices, are not covered by Medicare Part B under J2506. Do not imply coverage for indications outside myelosuppressive chemotherapy for non-myeloid malignancies.

Coverage limitations

• Coverage does not extend to myeloid malignancies (acute myeloid leukemia, chronic myeloid leukemia, etc.).
• Pegfilgrastim administered as a preventive measure outside of a chemotherapy regimen requires additional documentation of medical necessity.
• MAC-specific coverage articles may impose additional clinical criteria not reflected in the national CMS guidance.

Documentation requirements for J2506 claims

Incomplete documentation is one of the most common reasons J2506 claims are denied on audit. The following checklist reflects the requirements published in CMS coverage article A59126 and related MAC guidance. Practices using digital intake and clinical forms can structure their drug administration records to capture each item at the point of care.

• Cancer diagnosis: Chart notes must document the specific non-myeloid malignancy and ICD-10-CM code.
• Chemotherapy regimen: Document the specific myelosuppressive regimen the patient is receiving, including drug names, doses, and administration dates.
• Clinical indication: Physician attestation that pegfilgrastim is medically necessary to reduce febrile neutropenia risk in this patient.
• Administration record: Date, dose (confirm mg and unit count), route, delivery method (manual injection or on-body injector), and administering provider.
• Modifier documentation: JW or JZ modifier supported by drug preparation and waste records.
• Place of service: Confirm the setting matches the POS code billed on the claim.

Consistent clinical documentation practices are one of the highest-leverage investments a billing team can make. A single missing element, such as the chemotherapy regimen name, can hold up reimbursement for weeks.

Streamline your drug administration billing

Pabau helps oncology and infusion practices track HCPCS code updates, claim modifiers, and drug administration records so your billing team spends less time chasing denials.

Book a demo

Neulasta Onpro billing: a CPT distinction, not a separate drug code

A persistent myth in oncology billing is that the Neulasta Onpro on-body injector needs its own HCPCS drug code. It doesn’t.

Per CMS coverage article A54682 (and its successor articles covering the current biosimilars), the drug itself is billed the same way regardless of delivery method: J2506 for the originator product, or the matching biosimilar Q-code for a biosimilar. What changes with the Onpro device is the administration CPT code, not the drug HCPCS code.

The on-body injector is placed on the patient’s body by the provider at the end of a chemotherapy infusion. The pegfilgrastim dose is delivered automatically approximately 27 hours later without a return visit.

Before CPT 96377 became effective on January 1, 2017, providers used 96372 as an interim workaround for Onpro administrations. That workaround is long obsolete. CMS now expects 96377 specifically for the on-body injector, with 96372 reserved for the manual or prefilled-syringe injection.

Q4244 and Q4245 (used for skin substitute and wound-care products) have no connection to pegfilgrastim billing. If you see either of those codes anywhere in a Neulasta or Onpro drug table, that’s a data-entry error to correct immediately. Practices with infusion and drug administration workflows should build a protocol that captures the delivery method (manual vs. on-body injector) at the point of service entry, so the correct administration CPT code follows automatically.

Pegfilgrastim biosimilars and their HCPCS codes

Several FDA-approved pegfilgrastim biosimilars are available in the US market. Each biosimilar has its own HCPCS Q-code, distinct from J2506, which is reserved for the originator product. Using J2506 to bill a biosimilar is a billing error, and so is mixing up which Q-code belongs to which brand.

The table below lists the current 2026 biosimilar codes. Verify each code against the current AAPC HCPCS code range lookup and the CMS HCPCS annual update files, as biosimilar code assignments are updated when new products receive FDA approval.

Note on biosimilar interchangeability: FDA-approved biosimilar status does not automatically mean a product is designated “interchangeable” under FDA rules, which allows automatic substitution at the pharmacy level. Billing teams should code for the product actually administered, not based on assumed substitution. State pharmacy laws governing interchangeable dispensing vary.

Also worth flagging: Q5101 (filgrastim-sndz, brand name Zarxio) is sometimes pulled into pegfilgrastim crosswalks by mistake. It’s a biosimilar of filgrastim, a related but distinct short-acting G-CSF. It’s not a pegfilgrastim biosimilar, and it’s not billable for a pegfilgrastim administration.

2026 reimbursement rates for HCPCS code J2506

Medicare Part B reimburses J2506 under the Average Sales Price (ASP) methodology at ASP + 6% for both physician office and hospital outpatient department (HOPD) settings, per standard CMS ASP drug payment policy.

The actual dollar reimbursement changes quarterly when CMS publishes updated ASP files. Because J2506 bills per 0.5 mg unit rather than per 6 mg dose, the per-unit rate looks smaller than the old J2505 per-unit rate even when the total payment for a 6 mg dose is unchanged. Compare total dose payment, not the headline per-unit figure, when reviewing fee schedules.

Because ASP rates update four times per year, any specific dollar figure quoted here would be outdated within months. For current rates, consult the CMS ASP drug pricing files, published on the CMS website each quarter.

Use the PGM Billing HCPCS lookup tool for a quick cross-reference of current payment amounts using CMS data.

Common billing errors and denial reasons for J2506

The switch from J2505 to J2506 created a new set of denial patterns on top of the pre-existing ones. The following denial patterns come from published CMS coverage articles, MAC billing instructions, and common MUE edit patterns for injectable oncology drugs.

Practices that track drug administration billing through a system with built-in edit logic catch most of these errors before submission.

J2505 isn’t the only HCPCS code CMS has deleted and replaced in recent years. J3370 and J1040 followed the same pattern, so a periodic crosswalk audit should flag stale references to all of them, not just this one.

The same discipline applies to every high-cost Part B drug a practice bills, not just pegfilgrastim. Immune globulin products like J1569 carry their own unit and NDC-matching rules that are just as easy to get wrong.

For practices building or auditing their billing protocols, the patient care management guide covers documentation structure across service types.

J2505 to J2506 crosswalk: related codes

Coders working with G-CSF agents frequently cross-reference J2506 against related filgrastim and pegfilgrastim codes, plus the administration CPT codes that go alongside the drug code. The table below maps the codes most commonly referenced in this drug class. Verify all codes against the CMS 2026 HCPCS annual update file for current active status before billing.

Filgrastim (Neupogen) and pegfilgrastim are both G-CSF agents but are distinct drugs with different half-lives, dosing schedules, and HCPCS codes. Never use J2506 to bill a filgrastim administration, or vice versa.

For practice management software handling multiple drug codes, maintaining a current HCPCS drug table that maps each NDC to its correct code, and flags deleted codes automatically, is a front-line defense against crosswalk errors.

Conclusion

J2505 is gone, and it isn’t coming back. CMS deleted it effective December 31, 2021, with no grace period. Every pegfilgrastim claim for a current date of service needs J2506, billed at 0.5 mg per unit (12 units for a standard 6 mg dose), the correct administration CPT code for the delivery method used (96372 or 96377), the JW or JZ waste modifier, and the biosimilar Q-code that matches the actual product administered when a biosimilar was used. Getting each element right is the difference between a clean claim and a denial that sits in a worklist for three weeks.

Pabau’s claims management tools help oncology and infusion practices build the code-level rules and documentation prompts that prevent these errors before submission, including flagging a deleted code like J2505 before it ever reaches a claim. To see how it fits a drug administration workflow, book a demo.

Continue your research

List Item #1

List Item #2

Frequently asked questions